OSE Immunotherapeutics SA (EPA:OSE)
2.042
-0.028 (-1.35%)
Oct 22, 2026, 5:35 PM CEST
OSE Immunotherapeutics Employees
OSE Immunotherapeutics had 64 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes OSE Immunotherapeutics the 33,945th largest employer in the world and 439th in France.
Employees
64
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
€42,047
Profits / Employee
€588,891
Market Cap
48.03M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 64 | 0 | - |
| Dec 31, 2024 | 64 | 9 | 16.36% |
| Dec 31, 2023 | 55 | -12 | -17.91% |
| Dec 31, 2022 | 67 | 6 | 9.84% |
| Dec 31, 2021 | 61 | 10 | 19.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| genOway Société anonyme | 163 |
| Innate Pharma | 120 |
| Adocia | 80 |
| Sensorion | 66 |
| Fermentalg | 64 |
| MaaT Pharma | 60 |
| ABIONYX Pharma | 49 |
OSE Immunotherapeutics News
- Just now - OSE Immunotherapeutics Press release: KOL event - Filings
- 2 days ago - OSE Immunotherapeutics Transcript: Chardan's 10th Annual Healthcare Conference - Transcripts
- 24 days ago - OSE Immunotherapeutics Earnings release: Trading update - Filings
- 24 days ago - OSE Immunotherapeutics Highlights Pipeline Progress As Phase 3 Tedopi Study Advances - Nasdaq
- 7 weeks ago - OSE Immunotherapeutics Transcript: Study result - Transcripts
- 4 months ago - OSE Immunotherapeutics Transcript: Status update - Transcripts
- 4 months ago - OSE Immunotherapeutics Slides: Status update - Filings
- 4 months ago - OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document - GlobeNewsWire